DelveInsight’s “Netherton Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Netherton Syndrome, historical and forecasted epidemiology as well as the Netherton Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Netherton Syndrome market report provides current treatment practices, emerging drugs, Netherton Syndrome market share of the individual therapies, current and forecasted Netherton Syndrome market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Netherton Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Netherton Syndrome market.
Some of the key facts of the Netherthone Syndrome Market Report:
In the United States, the severe cases of Netherton Syndrome were estimated to be 184 cases in 2020 which are expected to rise during the study period 2018–2030.
The incidence and prevalence of NS have been estimated to be 1/200,000 births and 1–9/million, respectively; similar numbers are published in most of the literature available worldwide. Moreover, it has been reported that that NS could account for up to 18% of congenital erythroderma (Orphanet, 2021).
Key Benefits of the Netherthone Syndrome Report:
The report covers the descriptive overview of Netherton Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Netherton Syndrome epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Netherton Syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of the Netherton Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Netherton Syndrome market
Got queries? Click here to learn more about the Netherthone Syndrome Market Landscape
Netherton Syndrome Overview
Netherton syndrome (NS) is a rare autosomal recessive syndromic ichthyosis caused by mutations of the SPINK5 gene, which encodes the lymphoepithelial Kazal-type-related inhibitor (LEKTI) protein.The exact incidence of NS is unknown, partly because it is difficult to diagnose.
With around 150 cases reported in the scientific literature, it is estimated that approximately 1/200,000 people worldwide have NS. Symptoms are present at birth and include red, scaly skin. Other symptoms include outbreaks of red, circular scaly rashes, thin, fragile hair (bamboo hair), and immune reactions such as hay fever, asthma, itchy skin, and eczema. Dehydration and infection are common and can be serious. Babies tend to grow slowly and have poor weight gain. NS is diagnosed based on the symptoms and confirmed by genetic testing for changes in the SPINK5 gene. Other types of testing, such as close examination of the hair and a skin biopsy to obtain a small skin sample for examination under the microscope, can also be helpful for diagnosis. The disease in the neonatal period must be distinguished from several other disorders with extensive scaling erythroderma, failure to thrive, and increased risk of infection, particularly several immunodeficiency disorders, other ichthyoses, and atopic or psoriasiform erythroderma.
Netherthone Syndrome Epidemiological Insights:
As per the National Organization of Rare Disorders (NORD) (n.d.), NS is a rare hereditary disorder with approximately 150 cases reported in the medical literature. However, the actual number of affected individuals may be much higher due to diagnostic difficulties and overlapping symptoms with common atopic dermatitis and other congenital ichthyoses.
As per DelveInsight’s assessment, in 2020, the prevalent cases of Netherton Syndrome in the United States were found to be 1,658 which is projected to increase.
Netherton Syndrome Market Outlook
The Netherton Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Netherton Syndrome market trends by analyzing the impact of current Netherton Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Netherton Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Netherton Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Netherton Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Netherthone Syndrome Market Trends
Netherton Syndrome Key Companies
Lifemax Laboratories
AnaptysBio
Jassen Biotech
And many more
Netherton Syndrome Therapies
LM-030
Imsidolimab
Ustekinumab
Table of Contents
Key Insights
Report Introduction
Executive Summary of Netherthone Syndrome
Disease Background and Overview
Epidemiology and patient population
Netherthone Syndrome Emerging Therapies
Netherthone Syndrome Market Outlook
Market Access and Reimbursement of Therapies
Appendix
Netherthone Syndrome Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
Click here to read more about Netherthone Syndrome Market Insight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/